The firm has not published validation studies for the test, but new data last week has provided more support for the methylation-based method at its heart.
The company acquired GnuBio, which was developing a droplet-based sequencing platform, in 2014 for $39.7 million in cash and $10 million in contingent payments.
The company believes its product, called Constellation, will differentiate itself from current commercial offerings in terms of throughput and multiplexing capability.
Investigators plan to use the method in future longitudinal monitoring studies based on the sensitivity and ease demonstrated in their early experiments.
The sales decline was largely due to a slowdown in productivity related to the recent launch of the company's global enterprise resource planning system in Western Europe.
Investigators using droplet digital PCR methods are following cell-free tumor DNA in the blood, looking for patterns coinciding with immunotherapy treatment outcomes.
